https://scholars.lib.ntu.edu.tw/handle/123456789/519454
標題: | Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan | 作者: | Chang C.-J. Chou T.-C. Chang C.-C. TA-FU CHEN Hu C.-J. Fuh J.-L. Wang W. Chen C.-M. Hsu W. Huang C.-C. |
關鍵字: | Adherence; Donepezil; National Health Insurance Research Database; Persistence; Rivastigmine | 公開日期: | 2019 | 出版社: | Elsevier Inc | 卷: | 5 | 起(迄)頁: | 46-51 | 來源出版物: | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 摘要: | Introduction: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. Results: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. Discussion: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined. ? 2018 The Authors |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060751501&doi=10.1016%2fj.trci.2018.06.013&partnerID=40&md5=1146aac984917eedad06525f05e2754d https://scholars.lib.ntu.edu.tw/handle/123456789/519454 |
ISSN: | 2352-8737 | DOI: | 10.1016/j.trci.2018.06.013 | SDG/關鍵字: | donepezil; rivastigmine; adult; Article; comparative study; controlled study; dementia; drug dose increase; female; human; long term care; major clinical study; male; national health insurance; patient compliance; prescription; priority journal; retrospective study; Taiwan; treatment duration; treatment outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。